The present invention provides novel 16-ene-C25-oxime and 16-ene-C-25-oxime ether
analogs of 1,25-dihydroxy vitamin D3, compositions comprising
these compounds and methods of using these compounds as inhibitors of CYP24. In
particular, the compound of Formula I are useful for treating diseases which benefit
from a modulation of the levels of 1,25-dihydroxy vitamin D3,
for example, cell-proliferative disorders.
